Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$13.95
+2.3%		$14.35
$12.96
▼
$20.90
$294.52M0.7677,914 shs38,500 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-1.80%-5.08%-8.46%-11.09%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$13.95
+2.3%		$14.35
$12.96
▼
$20.90
$294.52M0.7677,914 shs38,500 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-1.80%-5.08%-8.46%-11.09%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.33
Sell$13.00-6.81% Downside

Current Analyst Ratings Breakdown

Latest AMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageUnderweight$13.00
8/17/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/17/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/16/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$213.65M1.38$0.37 per share37.76$22.07 per share0.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$38.80M-$0.99N/AN/AN/A-14.56%-0.20%-0.14%11/4/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.67
2.67

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
4.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36021.12 million20.23 millionOptionable

Recent News About These Companies

Amarin (NASDAQ:AMRN) vs. Royalty Pharma (NASDAQ:RPRX) Critical Contrast
September 6 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31007356
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
August 31, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/amarin-highlights-reduce-mechanistic-data-121500052.html
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
August 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353285/18362/en/amarin-highlights-new-reduce-it-and-mechanistic-data-presented-at-european-society-of-cardiology-esc-congress-2026.html
Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits
August 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4638065-amarin-analysis-links-vascepa-adherence-to-greater-longer-lasting-heart-benefits
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment ...
August 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/new-reduce-it-legacy-analysis-presented-at-european-society-of-cardiology-esc-congress-2026-suggests-persistent-cardiovascular-benefit-following-icosapent-ethyl-treatment-cessation-in-adherent-1036502783
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
August 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/reduce-legacy-analysis-presented-european-121500031.html
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352671/18362/en/new-reduce-it-legacy-analysis-presented-at-european-society-of-cardiology-esc-congress-2026-suggests-persistent-cardiovascular-benefit-following-icosapent-ethyl-treatment-cessation.html
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
August 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/analyses-reduce-epa-mechanistic-data-121500277.html
Amarin to Present New REDUCE-IT and EPA Analyses at ESC Congress 2026
August 24, 2026  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/34949/amarin-to-present-new-reduce-it-and-epa-analyses-at-esc-congress-2026
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
August 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/24/3349705/18362/en/new-analyses-from-reduce-it-and-epa-mechanistic-data-to-be-presented-at-the-european-society-of-cardiology-esc-congress-2026.html
JPMorgan Chase & Co. Begins Coverage on Amarin (NASDAQ:AMRN)
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-begins-coverage-on-amarin-nasdaqamrn-2026-08-21/
Amarin (NASDAQ:AMRN) Lowered to "Hold" Rating by Zacks Research
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/amarin-nasdaqamrn-lowered-to-hold-rating-by-zacks-research-2026-08-19/
Amarin (AMRN) Q2 2026 Earnings Call Transcript
August 7, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/08/07/amarin-amrn-q2-2026-earnings-call-transcript/
Amarin Earnings Call: Cost Cuts, Cash Strength, Mixed Sales
August 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/AMRN-Q/pressreleases/3604695/amarin-earnings-call-cost-cuts-cash-strength-mixed-sales/
Amarin expects positive full-year 2026 cash flow as VASCEPA market share reaches 48% and Europe demand rises 69%
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4621087-amarin-expects-positive-full-year-2026-cash-flow-as-vascepa-market-share-reaches-48-percent
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
July 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927298-amarin-corporation-plc-amrn-q2-2026-earnings-call-transcript
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/amarins-q2-earnings-beat-estimates-161700157.html
Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/amarin-corp-plc-amrn-q2-190356449.html
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
July 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2963707/amarin-s-q2-earnings-beat-estimates-revenues-fall-short?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2963707
Amarin Reports Second-Quarter Results as Partnered International Strategy Gains Momentum
July 29, 2026  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/33008/amarin-reports-second-quarter-results-as-partnered-international-strategy-gains-momentum
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/amarin-reports-2026-second-quarter-110000481.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$13.95 +0.32 (+2.35%)
As of 01:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas